Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.

IF 5.7 2区 医学 Q1 ONCOLOGY International Journal of Cancer Pub Date : 2024-11-14 DOI:10.1002/ijc.35251
Allan Jensen, Sonia Guleria, Vanna Albieri, Bugge Nøhr, Kirsten Frederiksen, Susanne K Kjær
{"title":"Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.","authors":"Allan Jensen, Sonia Guleria, Vanna Albieri, Bugge Nøhr, Kirsten Frederiksen, Susanne K Kjær","doi":"10.1002/ijc.35251","DOIUrl":null,"url":null,"abstract":"<p><p>Whether fertility treatment increases the risk of ovarian cancer has been a concern for many decades, but previous research has yielded conflicting findings. We therefore investigated this association within a large population-based cohort study of infertile women aged 20-45 years and living in Denmark between 1995 and 2017, as identified in the Danish Infertility Cohort (n = 146,110). The study cohort was linked to nationwide registers to obtain information on fertility drug use, cancer diagnoses, covariates, emigration, and vital status was. Hazard ratios (HR) and 95% confidence intervals (CI) with adjustment for potential confounders for ovarian cancer overall and for serous ovarian cancer were estimated using Cox proportional hazard models. During a median 10.3 years of follow-up, 114 women were diagnosed with ovarian cancer of which 65 had serous ovarian cancer. Our results showed that the rate of serous ovarian cancer (HR 1.92; 95% CI 1.16-3.17) was increased after every use of progesterone but the association was not affected by increased follow-up time since first use or with increased cumulative dose. We performed a secondary analysis adding less extensive data from 1971 through 1994 from the Danish Infertility Cohort. In this study cohort, 332 women developed ovarian cancer of which 192 had serous ovarian cancer. The overall results were similar, including the association between every use of progesterone and serous ovarian cancer (HR 2.05: 95% CI: 1.31-3.21). In conclusion, the novel finding that use of progesterone is associated with an increased rate of serous ovarian cancer warrants further investigation.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ijc.35251","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Whether fertility treatment increases the risk of ovarian cancer has been a concern for many decades, but previous research has yielded conflicting findings. We therefore investigated this association within a large population-based cohort study of infertile women aged 20-45 years and living in Denmark between 1995 and 2017, as identified in the Danish Infertility Cohort (n = 146,110). The study cohort was linked to nationwide registers to obtain information on fertility drug use, cancer diagnoses, covariates, emigration, and vital status was. Hazard ratios (HR) and 95% confidence intervals (CI) with adjustment for potential confounders for ovarian cancer overall and for serous ovarian cancer were estimated using Cox proportional hazard models. During a median 10.3 years of follow-up, 114 women were diagnosed with ovarian cancer of which 65 had serous ovarian cancer. Our results showed that the rate of serous ovarian cancer (HR 1.92; 95% CI 1.16-3.17) was increased after every use of progesterone but the association was not affected by increased follow-up time since first use or with increased cumulative dose. We performed a secondary analysis adding less extensive data from 1971 through 1994 from the Danish Infertility Cohort. In this study cohort, 332 women developed ovarian cancer of which 192 had serous ovarian cancer. The overall results were similar, including the association between every use of progesterone and serous ovarian cancer (HR 2.05: 95% CI: 1.31-3.21). In conclusion, the novel finding that use of progesterone is associated with an increased rate of serous ovarian cancer warrants further investigation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
丹麦全国不孕妇女大样本中的生育治疗与卵巢癌风险。
几十年来,生育治疗是否会增加卵巢癌风险一直是人们关注的问题,但以往的研究结果却相互矛盾。因此,我们在一项基于人群的大型队列研究中调查了这一关联,研究对象是丹麦不孕不育队列(n = 146,110 人)中确定的 1995 年至 2017 年期间居住在丹麦的 20-45 岁不孕不育女性。该研究队列与全国范围内的登记簿相连接,以获得有关生育药物使用、癌症诊断、协变量、移民和生命状态的信息。使用 Cox 比例危险模型估算了卵巢癌总体患病率和浆液性卵巢癌患病率的危险比 (HR) 和 95% 置信区间 (CI),并对潜在的混杂因素进行了调整。在中位 10.3 年的随访期间,有 114 名妇女被诊断出患有卵巢癌,其中 65 人患有浆液性卵巢癌。我们的结果表明,每次使用黄体酮后,浆液性卵巢癌的发病率(HR 1.92;95% CI 1.16-3.17)都会升高,但首次使用后随访时间的延长或累积剂量的增加都不会影响这种关联。我们进行了二次分析,增加了丹麦不孕不育队列从 1971 年到 1994 年的较少数据。在这个研究队列中,有 332 名妇女罹患卵巢癌,其中 192 人罹患浆液性卵巢癌。总体结果相似,包括每次使用黄体酮与浆液性卵巢癌之间的关联(HR 2.05:95% CI:1.31-3.21)。总之,使用黄体酮与浆液性卵巢癌发病率增加有关的新发现值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
13.40
自引率
3.10%
发文量
460
审稿时长
2 months
期刊介绍: The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories: -Cancer Epidemiology- Cancer Genetics and Epigenetics- Infectious Causes of Cancer- Innovative Tools and Methods- Molecular Cancer Biology- Tumor Immunology and Microenvironment- Tumor Markers and Signatures- Cancer Therapy and Prevention
期刊最新文献
Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women. Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States. Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database. Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS. Maternal illnesses during pregnancy and the risk of childhood cancer: A medical-record based analysis (UKCCS).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1